Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function

Maximizing baseline function of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) is essential for their effective application in models of cardiac toxicity and disease. Here, we aimed to identify factors that would promote an adequate level of function to permit robust single-cell contr...

Full description

Bibliographic Details
Main Authors: Matthew J. Birket, Marcelo C. Ribeiro, Georgios Kosmidis, Dorien Ward, Ana Rita Leitoguinho, Vera van de Pol, Cheryl Dambrot, Harsha D. Devalla, Richard P. Davis, Pier G. Mastroberardino, Douwe E. Atsma, Robert Passier, Christine L. Mummery
Format: Article
Language:English
Published: Elsevier 2015-10-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124715010360
Description
Summary:Maximizing baseline function of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) is essential for their effective application in models of cardiac toxicity and disease. Here, we aimed to identify factors that would promote an adequate level of function to permit robust single-cell contractility measurements in a human induced pluripotent stem cell (hiPSC) model of hypertrophic cardiomyopathy (HCM). A simple screen revealed the collaborative effects of thyroid hormone, IGF-1 and the glucocorticoid analog dexamethasone on the electrophysiology, bioenergetics, and contractile force generation of hPSC-CMs. In this optimized condition, hiPSC-CMs with mutations in MYBPC3, a gene encoding myosin-binding protein C, which, when mutated, causes HCM, showed significantly lower contractile force generation than controls. This was recapitulated by direct knockdown of MYBPC3 in control hPSC-CMs, supporting a mechanism of haploinsufficiency. Modeling this disease in vitro using human cells is an important step toward identifying therapeutic interventions for HCM.
ISSN:2211-1247